vs
Side-by-side financial comparison of CXApp Inc. (CXAI) and PMV Pharmaceuticals, Inc. (PMVP). Click either name above to swap in a different company.
PMV Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($1.2M vs $1.0M, roughly 1.2× CXApp Inc.). CXApp Inc. runs the higher net margin — -544.1% vs -1464.0%, a 919.9% gap on every dollar of revenue. On growth, CXApp Inc. posted the faster year-over-year revenue change (-38.5% vs -46.1%). CXApp Inc. produced more free cash flow last quarter ($-3.6M vs $-17.2M). Over the past eight quarters, CXApp Inc.'s revenue compounded faster (-25.0% CAGR vs -35.4%).
CXApp Inc. is a technology firm specializing in digital workplace experience solutions. It offers cloud-based software tools for employee engagement, office space optimization, visitor management, and hybrid work coordination, serving mid-to-large enterprises across North America, APAC and Europe.
PMV Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies targeting mutations in the p53 tumor suppressor gene, one of the most frequently altered genes in human cancers. Its lead product candidates address unmet medical needs for patients with hard-to-treat solid and hematologic malignancies, serving global oncology patient segments.
CXAI vs PMVP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.2M |
| Net Profit | $-5.6M | $-18.0M |
| Gross Margin | 86.9% | — |
| Operating Margin | -576.9% | -1561.8% |
| Net Margin | -544.1% | -1464.0% |
| Revenue YoY | -38.5% | -46.1% |
| Net Profit YoY | -56.7% | 21.6% |
| EPS (diluted) | — | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $1.2M | ||
| Q3 25 | $1.1M | $1.5M | ||
| Q2 25 | $1.2M | $1.7M | ||
| Q1 25 | $1.2M | $1.9M | ||
| Q4 24 | $1.7M | $2.3M | ||
| Q3 24 | $1.9M | $2.6M | ||
| Q2 24 | $1.8M | $2.8M | ||
| Q1 24 | $1.8M | $3.0M |
| Q4 25 | $-5.6M | $-18.0M | ||
| Q3 25 | $-3.2M | $-21.1M | ||
| Q2 25 | $-3.1M | $-21.2M | ||
| Q1 25 | $-1.6M | $-17.4M | ||
| Q4 24 | $-3.5M | $-23.0M | ||
| Q3 24 | $-5.4M | $-19.2M | ||
| Q2 24 | $-5.3M | $-1.2M | ||
| Q1 24 | $-5.2M | $-15.3M |
| Q4 25 | 86.9% | — | ||
| Q3 25 | 89.0% | — | ||
| Q2 25 | 86.0% | — | ||
| Q1 25 | 87.7% | — | ||
| Q4 24 | 86.0% | — | ||
| Q3 24 | 80.4% | — | ||
| Q2 24 | 80.0% | — | ||
| Q1 24 | 82.0% | — |
| Q4 25 | -576.9% | -1561.8% | ||
| Q3 25 | -343.4% | -1521.8% | ||
| Q2 25 | -336.1% | -1353.8% | ||
| Q1 25 | -306.0% | -1114.4% | ||
| Q4 24 | -169.7% | -1100.5% | ||
| Q3 24 | -194.3% | -837.0% | ||
| Q2 24 | -206.7% | -720.1% | ||
| Q1 24 | -197.3% | -617.2% |
| Q4 25 | -544.1% | -1464.0% | ||
| Q3 25 | -283.4% | -1422.9% | ||
| Q2 25 | -256.7% | -1255.0% | ||
| Q1 25 | -132.0% | -901.1% | ||
| Q4 24 | -213.6% | -1005.7% | ||
| Q3 24 | -286.5% | -735.2% | ||
| Q2 24 | -297.6% | -43.3% | ||
| Q1 24 | -284.4% | -517.3% |
| Q4 25 | — | $-0.33 | ||
| Q3 25 | — | $-0.40 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.34 | ||
| Q4 24 | — | $-0.45 | ||
| Q3 24 | — | $-0.37 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.1M | $112.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $14.0M | $104.7M |
| Total Assets | $32.4M | $116.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.1M | $112.9M | ||
| Q3 25 | $5.1M | $129.3M | ||
| Q2 25 | $4.9M | $142.3M | ||
| Q1 25 | $3.9M | $160.4M | ||
| Q4 24 | $4.9M | $169.5M | ||
| Q3 24 | — | $182.8M | ||
| Q2 24 | — | $212.9M | ||
| Q1 24 | — | $197.9M |
| Q4 25 | $14.0M | $104.7M | ||
| Q3 25 | $15.2M | $121.0M | ||
| Q2 25 | $14.3M | $140.6M | ||
| Q1 25 | $15.6M | $160.1M | ||
| Q4 24 | $15.6M | $176.1M | ||
| Q3 24 | $13.6M | $197.9M | ||
| Q2 24 | $16.3M | $214.3M | ||
| Q1 24 | $20.9M | $212.7M |
| Q4 25 | $32.4M | $116.6M | ||
| Q3 25 | $28.5M | $133.8M | ||
| Q2 25 | $29.6M | $152.9M | ||
| Q1 25 | $29.3M | $170.6M | ||
| Q4 24 | $31.8M | $191.3M | ||
| Q3 24 | — | $223.5M | ||
| Q2 24 | — | $237.5M | ||
| Q1 24 | — | $236.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.6M | $-17.2M |
| Free Cash FlowOCF − Capex | $-3.6M | $-17.2M |
| FCF MarginFCF / Revenue | -355.5% | -1396.4% |
| Capex IntensityCapex / Revenue | 0.2% | 1.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-10.4M | $-73.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.6M | $-17.2M | ||
| Q3 25 | $-2.8M | $-19.8M | ||
| Q2 25 | $-3.0M | $-18.3M | ||
| Q1 25 | $-979.0K | $-18.3M | ||
| Q4 24 | $-2.7M | $-16.7M | ||
| Q3 24 | $-2.1M | $-16.8M | ||
| Q2 24 | $-1.9M | $-1.6M | ||
| Q1 24 | $-650.0K | $-16.2M |
| Q4 25 | $-3.6M | $-17.2M | ||
| Q3 25 | $-2.8M | $-19.8M | ||
| Q2 25 | $-3.0M | $-18.3M | ||
| Q1 25 | $-984.0K | $-18.3M | ||
| Q4 24 | — | $-16.7M | ||
| Q3 24 | $-2.1M | $-16.8M | ||
| Q2 24 | $-1.9M | $-1.6M | ||
| Q1 24 | $-668.0K | $-16.8M |
| Q4 25 | -355.5% | -1396.4% | ||
| Q3 25 | -248.1% | -1339.3% | ||
| Q2 25 | -247.2% | -1083.6% | ||
| Q1 25 | -80.4% | -944.2% | ||
| Q4 24 | — | -731.0% | ||
| Q3 24 | -109.3% | -644.0% | ||
| Q2 24 | -108.6% | -57.2% | ||
| Q1 24 | -36.7% | -568.4% |
| Q4 25 | 0.2% | 1.2% | ||
| Q3 25 | 0.4% | 0.1% | ||
| Q2 25 | 0.9% | 0.7% | ||
| Q1 25 | 0.4% | 0.2% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.5% | 0.1% | ||
| Q1 24 | 1.0% | 20.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
